RN Mobile Menu

Search form


Rheumatology Network

Cold fingers? Is it primary or secondary Raynaud’s?

Raynaud’s phenomenon affects up to 5% of the general population, but for 37% of patients, it leads to connective tissue disease. In this slideshow, we compare primary and secondary Raynaud’s.  (Raynaud’s phenomenon, ©Twinschoice/Shutterstock.com)

Recent Content


In this slideshow, we highlight some of the upcoming studies due to be presented at the American College of Rheumatology 2016 annual meeting which begins Nov. 11 in Washington, D.C.


PsA patients show sustained improvement at two years with secukinumab, clinical trial shows.

Lymphocyte. Immune cell. (©Toey/Shutterstock.com)

Innate lymphocytes may have a role as disease targets in rheumatoid arthritis, psoriatic arthritis and/or inflammatory bowel disease, researchers say.

(Drug development ©BrigidSturgeonShutterstock.com)

In this article, we discuss the possibility of innate lymphocytes as therapeutic targets in rheumatic disease as described in Nature Reviews Rheumatology.


The 2015 recommendations for PsA treatment highlight the importance of managing comorbidities and a patient-centered treatment approach.


Researchers rank febuxostat as the most effective urate-lowering drug for reaching serum uric acid targets for gout patients.


How do rheumatologists and primary care physicians differ in treating patients with gout? This survey highlights some notable differences.

By clicking Accept, you agree to become a member of the UBM Medica Community.